Ask AI
Case Challenge: NSCLC

CE / CME

Biomarker Testing in Patients With Solid Tumors: Interactive Case Challenge for NSCLC

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Released: June 16, 2026

Expiration: December 15, 2026

Activity

Progress
1 2
Course Completed

  1. Amivantamab-vmjw [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025.
  2. Lazertinib [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2026.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Non-small cell lung cancer. v.1.2026. nccn.org. Accessed June 8, 2026.
  4. Mok TS, Solomon BJ, Felip E, et al. Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study. J Clin Oncol. 2026;44(suppl 16):8502.
  5. Leighl NB, Ismaila N, Durm G, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2024. J Clin Oncol. 2025;43:677.
  6. Reuss JE, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2026.3.0. J Clin Oncol. 2026.
  7. Hendriks LEL, Cortiula F, Martins-Branco D, et al. Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline. Ann Oncol. 2025;36:1227-1231.
  8. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. J Thorac Oncol. 2018;13:323-358.
  9. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40:1231-1258.
  10. Osimertinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
  11. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339.
  12. Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278.
  13. Lee J, Piotrowska Z, Soo R, et al. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Ther Adv Med Oncol. 2022;14:17588359221144099.
  14. Brahmer JR, Govindan R, Ander RA, et al. The society for Immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6:75.
  15. Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme LLC; 2025.
  16. Lorlatinib [prescribing information]. New York, NY: Pfizer Inc.; 2026.
  17. Crizotinib [prescribing information]. New York, NY: Pfizer Labs; 2022.
  18. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018-2029.
  19. Solomon 2022.
  20. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
  21. Jänne PA, Planchard D, Kobayashi K, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394:27-38.
  22. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391:1486-1498.
  23. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113.
  24. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-1948.
  25. Yang JCH, Lu S, Hayashi H, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393:1681-1693.
  26. Chan D W-K, Choi H C-W, and Lee V H-F. Treatment-related adverse events of combination EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor in EGFR-mutant advanced non-small cell lung cancer: a systematic review and meta-analysis. Cancers (Basel). 2022;14:2157.
  27. Belcher SM, Peng Y, Falzon L, et al. ONS Guidelines™ to support patient adherence to oral anticancer medications. Oncol Nurs Forum. 2022;49:279-295.
  28. Puri S, Leighl NB, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, 2026.3.0. J Clin Oncol. 2026;44:e15-e55.
  29. Alectinib [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2024.
  30. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056-1064.
  31. Brigatinib [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals America, Inc; 2026.
  32. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091-2108.
  33. Ceritinib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2026.
  34. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917-929.
  35. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-2177.
  36. Ensartinib [prescribing information]. Palm Beach Gardens, FL: Xcovery Holdings, Inc.; 2026.
  37. Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021;7:1617-1625.